An Update and Review of the Treatment of Myoclonus

Current Neurology and Neuroscience Reports

Volumn 15, Issue 1, 2015, Pages

  Mills, Kelly ^a   Mari, Zoltan ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cortical myoclonus; Cortical subcortical myoclonus; Deep brain stimulation; Movement disorder; Myoclonus treatment; Myoclonus dystonia; Segmental myoclonus; Subcortical nonsegmental myoclonus

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; BRIVARACETAM; CARBAMAZEPINE; CLONAZEPAM; CORTICOSTEROID; CORTICOTROPIN; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; IMMUNOGLOBULIN; LAMOTRIGINE; OFATUMUMAB; OXYBATE SODIUM; PHENYTOIN; PIRACETAM; PLACEBO; RITUXIMAB; TETRABENAZINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

AGRANULOCYTOSIS; APLASTIC ANEMIA; BEHAVIOR CHANGE; BODY WEIGHT DISORDER; BRAIN DEPTH STIMULATION; CHILDHOOD ABSENCE EPILEPSY; CLINICAL CLASSIFICATION; COGNITIVE DEFECT; DIZZINESS; DRUG DEPENDENCE; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSTONIA; ELECTROENCEPHALOGRAM; ELECTROMYOGRAM; EPILEPSY; EVOKED SOMATOSENSORY RESPONSE; HAIR LOSS; HEMIFACIAL SPASM; HUMAN; LIVER TOXICITY; METABOLIC ACIDOSIS; MYOCLONUS; MYOCLONUS DYSTONIA; MYOCLONUS EPILEPSY; NEPHROLITHIASIS; NONHUMAN; OPSOCLONUS MYOCLONUS SYNDROME; OSTEOPOROSIS; PARESTHESIA; RASH; REVIEW; REYE SYNDROME; SEDATION; SEIZURE; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; CLASSIFICATION;

HUMANS; MYOCLONUS;

EID: 84937210431     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-014-0512-2     Document Type: Review

References (108)

1. Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders. 2nd ed. 2011, Edinburgh; New York: Elsevier/Saunders. vii, 548 p.
2. Marsden CD, Hallett M, Fahn S. The nosology and pathophysiology of myoclonus. Movement Disorders, ed. C.D. Marsden and S. Fahn. 1982, London: Butterworths.
3. Espay AJ, Chen R. Myoclonus. Continuum. 2013;19(5 Movement Disorders):1264–86. This review approaches treatment of myoclonus from an etiology-specific algorithm, which can be clinically useful. It also has examples of the physiology associated with various types of myoclonus.
4. Caviness JN. Treatment of myoclonus. Neurother J Am Soc Exp NeuroTher. 2014;11(1):188–200. This is a good review of the classification and treatment of myoclonus with emphasis on the neurophysiologic classification, including examples of surface EMG, EEG, and EEG-EMG back-averaging in various types of myoclonus.
5. Brown P et al. Intrahemispheric and interhemispheric spread of cerebral cortical myoclonic activity and its relevance to epilepsy. Brain J Neurol. 1991;114(Pt 5):2333–51.
6. Rossi Sebastiano D et al. Cortical myoclonus in childhood and juvenile onset Huntington’s disease. Parkinsonism Relat Disord. 2012;18(6):794–7.
7. Obeso JA. Therapy of myoclonus. Clin Neurosci. 1995;3(4):253–7.
8. Fahn S. Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. Adv Neurol. 1979;26:49–84.
9. Saft C et al. Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington’s disease patients: a case series. BMC Neurol. 2006;6:11.
10. Brown P et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord Off J Mov Disord Soc. 1993;8(1):63–8.
11. Koskiniemi M et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry. 1998;64(3):344–8.
12. Obeso JA et al. Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol. 1988;11(6):529–36.
13. Frucht SJ et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology. 2001;57(6):1112–4.
14. Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord Int Epilepsy J Videotape. 2000;2(4):209–12.
15. Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia. 2004;45(6):678–81.
16. Cho JW, Lee JH. Suppression of myoclonus in corticobasal degeneration by levetiracetam. J Mov Disord. 2014;7(1):28–30.
17. Kovacs T et al. Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases. J Neural Transm. 2009;116(12):1631–4. The authors report a small series of two cases of corticobasal degeneration where levetiracetam produced a marked reduction in myoclonus on the UMRS when assessed by a blinded video rater. Doses were 1000 to 1500 mg/day and the effect lasted at least 3 years.
18. Orsucci D et al. Levetiracetam-responsive myoclonus in spinocerebellar ataxia type 15. Mov Disord. 2013;28(10):1465.
19. Biton V et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57–66. This study is a randomized, double-blind, placebo-controlled trial showing a reduction by 22% in seizure frequency in epilepsy patients with medication-refractory epilepsy. Further study should be done on brivaracetam for myoclonus.
20. Tai KK, Truong DD. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. J Neural Transm. 2007;114(12):1547–51.
21. Goldberb MA, Dorman JD. Intention myoclonus: successful treatment with clonazepam. Neurology. 1976;26(1):24–6.
22. Obeso JA et al. The treatment of severe action myoclonus. Brain J Neurol. 1989;112(Pt 3):765–77.
23. Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res. 1998;29(2):109–14.
24. Yoshimura I et al. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res. 2001;46(3):283–7.
25. Demir CF, Ozdemir HH, Mungen B. Efficacy of topiramate as add-on therapy in two different types of progressive myoclonic epilepsy. Acta Med (Hradec Kralove). 2013;56(1):36–8.
26. Miyahara A et al. Reassessment of phenytoin for treatment of late stage progressive myoclonus epilepsy complicated with status epilepticus. Epilepsy Res. 2009;84(2–3):201–9.
27. Genton P, Gelisse P, Crespel A. Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. Epilepsia. 2006;47(12):2083–5.
28. Gelisse P et al. Worsening of negative myoclonus by lamotrigine in a case of idiopathic focal epilepsy of children with long-term follow-up. Brain and Development. 2012;34(3):248–50.
29. Frucht SJ et al. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology. 2005;65(12):1967–9.
30. Kobayashi K et al. Thalamic deep brain stimulation for the treatment of action myoclonus caused by perinatal anoxia. Stereotact Funct Neurosurg. 2010;88(4):259–63.
31. Yamada K et al. Gpi pallidal stimulation for Lance-Adams syndrome. Neurology. 2011;76(14):1270–2. This case of GPi DBS for posthypoxic myoclonus (Lance-Adams syndrome) showed a significant reduction in the frequency of myoclonic jerks. As discussed above, the localization was not physiologically confirmed but the article may be pertinent for discussion.
32. Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol. 2004;3(10):598–607.
33. Marson AG et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016–26.
34. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998;29(2):147–54.
35. Machado RA et al. Efficacy and tolerability of lamotrigine in juvenile myoclonic epilepsy in adults: a prospective, unblinded randomized controlled trial. Seizure J Br Epilepsy Assoc. 2013;22(10):846–55.
36. Bodenstein-Sachar H et al. Outcome of lamotrigine treatment in juvenile myoclonic epilepsy. Acta Neurol Scand. 2011;124(1):22–7.
37. Beran RG et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia. 1998;39(12):1329–33.
38. Carrazana EJ, Wheeler SD. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology. 2001;56(10):1424–5.
39. Verrotti A et al. Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents. Dev Med Child Neurol. 2008;50(1):29–32.
40. Specchio N et al. Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy. Epilepsia. 2008;49(4):663–9.
41. Levisohn PM, Holland KD. Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison. Epilepsy Behav E&B. 2007;10(4):547–52.
42. Glauser TA et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54(1):141–55.
43. Kojovic M, Cordivari C, Bhatia K. Myoclonic disorders: a practical approach for diagnosis and treatment. Ther Adv Neurol Disord. 2011;4(1):47–62.
44. Esposito M et al. Idiopathic spinal myoclonus: a clinical and neurophysiological assessment of a movement disorder of uncertain origin. Mov Disord Off J Mov Disord Soc. 2009;24(16):2344–9.
45. van der Salm SM et al. Axial jerks: a clinical spectrum ranging from propriospinal to psychogenic myoclonus. J Neurol. 2010;257(8):1349–55. The authors report that 34 of 35 propriospinal myoclonus cases referred to their center were psychogenic based on clinical clues, inconsistent polymyography, or the presence of Bereitschaftspotential and that tic characteristics were also noted in many cases.
46. Roze E et al. Propriospinal myoclonus revisited: clinical, neurophysiologic, and neuroradiologic findings. Neurology. 2009;72(15):1301–9. The evaluation and treatment of 10 patients with secondary or presumed secondary (not psychogenic) myoclonus is reported. Zonisamide and levetiracetam offered some benefit when clonazepam was not helpful.
47. Hallett M et al. Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry. 1977;40(3):253–64.
48. Wong A. An update on opsoclonus. Curr Opin Neurol. 2007;20(1):25–31.
49. Jang W et al. Reversible propriospinal myoclonus due to thoracic disc herniation: long-term follow-up. J Neurol Sci. 2012;313(1–2):32–4.
50. Shprecher D, Silberstein H, Kurlan R. Propriospinal myoclonus due to cord compression in the absence of myelopathy. Mov Disord Off J Mov Disord Soc. 2010;25(8):1100–1.
51. Zamidei L et al. Propriospinal myoclonus following intrathecal bupivacaine in hip surgery: a case report. Minerva Anestesiol. 2010;76(4):290–3.
52. Maltete D et al. TENS for the treatment of propriospinal myoclonus. Mov Disord Off J Mov Disord Soc. 2008;23(15):2256–7.
53. Wojtecki L et al. Transient improvement of psychogenic (proprio-)spinal-like myoclonus to electrical nerve stimulation. Mov Disord Off J Mov Disord Soc. 2009;24(13):2024–5.
54. Quinn NP. Essential myoclonus and myoclonic dystonia. Mov Disord Off J Mov Disord Soc. 1996;11(2):119–24.
55. Przuntek H, Muhr H. Essential familial myoclonus. J Neurol. 1983;230(3):153–62.
56. Kuncel AM et al. Myoclonus and tremor response to thalamic deep brain stimulation parameters in a patient with inherited myoclonus-dystonia syndrome. Clin Neurol Neurosurg. 2009;111(3):303–6.
57. Trottenberg T et al. Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. Mov Disord Off J Mov Disord Soc. 2001;16(4):769–71.
58. Azoulay-Zyss J et al. Bilateral deep brain stimulation of the pallidum for myoclonus-dystonia due to epsilon-sarcoglycan mutations: a pilot study. Arch Neurol. 2011;68(1):94–8.
59. Contarino MF et al. Effect of pallidal deep brain stimulation on psychiatric symptoms in myoclonus-dystonia due to epsilon-sarcoglycan mutations. Arch Neurol. 2011;68(8):1087–8. author reply 1088–9.
60. Gruber D et al. Pallidal and thalamic deep brain stimulation in myoclonus-dystonia. Mov Disord Off J Mov Disord Soc. 2010;25(11):1733–43.
61. Starr PA. Deep brain stimulation for other tremors, myoclonus, and chorea. Handb Clin Neurol. 2013;116:209–15.
62. Rughani AI, Lozano AM. Surgical treatment of myoclonus dystonia syndrome. Mov Disord Off J Mov Disord Soc. 2013;28(3):282–7. This systematic review of all reported cases of myoclonus dystonia syndrome treated with deep brain stimulation offers a comparison between brain targets (GPi vs. Vim thalamus). It suggests that myoclonus improved similarly with both brain targets, though there was a paucity of studies reporting on outcomes with Vim DBS.
63. Weissbach A et al. Prominent psychiatric comorbidity in the dominantly inherited movement disorder myoclonus-dystonia. Parkinsonism Relat Disord. 2013;19(4):422–5.
64. van Tricht MJ et al. Cognition and psychopathology in myoclonus-dystonia. J Neurol Neurosurg Psychiatry. 2012;83(8):814–20.
65. Kuhn AA, et al. Early surgical treatment in a case of myoclonus dystonia syndrome. J Child Neurol. 2014. Treatment for Myoclonus-dystonia in a 17 year old is described in this case report. His UMRS improved by 89 % and there was a marked improvement in quality of life subjectively, indicating that early treatment for disabled patients should be studied further.
66. Bataller L et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain J Neurol. 2001;124(Pt 2):437–43.
67. Pranzatelli MR et al. B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord Off J Mov Disord Soc. 2010;25(2):238–42.
68. Ketterl TG et al. Ofatumumab for refractory opsoclonus-myoclonus syndrome following treatment of neuroblastoma. Pediatr Blood Cancer. 2013;60(12):E163–5. A case report of a patient with ANNA-1 antibody associated opsoclonus-myoclonus syndrome refractory to rituximab responded to a combination of ofatumumab and methotrexate, suggesting another possible treatment option to study in difficult cases.
69. Bartos A. Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis. Eur Neurol. 2006;56(4):240–2.
70. Caviness JN et al. The movement disorder of adult opsoclonus. Mov Disord Off J Mov Disord Soc. 1995;10(1):22–7.
71. Tijssen MA et al. The effects of clonazepam and vigabatrin in hyperekplexia. J Neurol Sci. 1997;149(1):63–7.
72. Chadwick D et al. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain J Neurol. 1977;100(3):455–87.
73. Caviness JN. Segmental myoclonus. In: Albanese A, Jankovic J, editors. Hyperkinetic movement disorders. Hoboken: John Wiley & Sons; 2012. p. 221–35.
74. Biller J, Espay AJ. Nosography of the “essential”: volitional palatal tremor. Neurology. 2013;81(8):772–3.
75. Stamelou M et al. Psychogenic palatal tremor may be underrecognized: reappraisal of a large series of cases. Mov Disord. 2012;27(9):1164–8. In a series of 17 patients with palatal tremor (formerly “myoclonus”), 10 had isolated palatal tremor. 70% of these had a psychogenic etiology, suggesting that psychogenic essential palatal tremor is more common than previously thought.
76. Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol. 1986;43(10):1025–31.
77. Lagueny A et al. Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A. Mov Disord. 1999;14(1):182–5.
78. Polo KB, Jabbari B. Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin. Mov Disord. 1994;9(2):233–5.
79. Keswani SC et al. Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry. 2002;73(4):457–8.
80. Chiodo AE, Saval A. Intrathecal baclofen for the treatment of spinal myoclonus: a case series. J Spinal Cord Med. 2012;35(1):64–7.
81. Penney SE, Bruce IA, Saeed SR. Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol. 2006;253(7):857–60.
82. Krause E, Heinen F, Gurkov R. Difference in outcome of botulinum toxin treatment of essential palatal tremor in children and adults. Am J Otolaryngol. 2010;31(2):91–5.
83. Scott BL, Evans RW, Jankovic J. Treatment of palatal myoclonus with sumatriptan. Mov Disord. 1996;11(6):748–51.
84. Jabbari B et al. Effectiveness of trihexyphenidyl against pendular nystagmus and palatal myoclonus: evidence of cholinergic dysfunction. Mov Disord. 1987;2(2):93–8.
85. Bakheit AM, Behan PO. Palatal myoclonus successfully treated with clonazepam. J Neurol Neurosurg Psychiatry. 1990;53(9):806.
86. Badia L, Parikh A, Brookes GB. Management of middle ear myoclonus. J Laryngol Otol. 1994;108(5):380–2.
87. Tan EK et al. Role of magnetic resonance imaging and magnetic resonance angiography in patients with hemifacial spasm. Ann Acad Med Singap. 1999;28(2):169–73.
88. Martinelli P, Giuliani S, Ippoliti M. Hemifacial spasm due to peripheral injury of facial nerve: a nuclear syndrome? Mov Disord. 1992;7(2):181–4.
89. Yoshimura DM et al. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve. 1992;15(9):1045–9.
90. Alexander GE, Moses 3rd H. Carbamazepine for hemifacial spasm. Neurology. 1982;32(3):286–7.
91. Daniele O et al. Gabapentin in the treatment of hemifacial spasm. Acta Neurol Scand. 2001;104(2):110–2.
92. Kaye AH, Adams CB. Hemifacial spasm: a long term follow-up of patients treated by posterior fossa surgery and facial nerve wrapping. J Neurol Neurosurg Psychiatry. 1981;44(12):1100–3.
93. Terada K et al. Presence of Bereitschaftspotential preceding psychogenic myoclonus: clinical application of jerk-locked back averaging. J Neurol Neurosurg Psychiatry. 1995;58(6):745–7.
94. Hinson VK et al. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord. 2006;12(3):177–80.
95. Kompoliti K et al. Immediate vs. delayed treatment of psychogenic movement disorders with short term psychodynamic psychotherapy: randomized clinical trial. Parkinsonism Relat Disord. 2014;20(1):60–3. Fifteen patients with a psychogenic movement disorder were followed by a neurologist but treated with immediate (n = 7) or delayed (n = 8) psychodynamic psychotherapy. Time was the only factor in PMD improvement, independent of group assignment.
96. Goldberg S et al. Serotonin modulation of cerebral glucose metabolism in normal aging. Neurobiol Aging. 2004;25(2):167–74.
97. Bosch OG et al. Reconsidering GHB: orphan drug or new model antidepressant? J Psychopharmacol. 2012;26(5):618–28.
98. Frucht SJ et al. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord Off J Mov Disord Soc. 2005;20(10):1330–7. This case series includes two patients with ethanol-responsive myoclonus-dystonia (SGCE mutation positive) who had >50% improvement in the UMRS (blinded video rater) when treated with sodium oxybate at 2.5 g TID or 3.5 g BID.
99. Sumnall HR et al. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend. 2008;92(1–3):286–90.
100. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS drugs. 2002;16(10):669–94.
101. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther. 1986;237(3):1001–11.
102. Whittle SR, Turner AJ. Effects of anticonvulsants on the formation of gamma-hydroxybutyrate from gamma-aminobutyrate in rat brain. J Neurochem. 1982;38(3):848–51.
103. Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323–38.
104. Daniels V et al. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays. Br J Pharmacol. 2013;169(5):1091–101.
105. Mbizvo GK, et al. The adverse effects profile of levetiracetam in epilepsy: a more detailed look. Int J Neurosci. 2013.
106. Mula M. Brivaracetam for the treatment of epilepsy in adults. Expert Rev Neurother. 2014;14(4):361–5.
107. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007;30(4):230–40.
108. Greenfield Jr LJ. Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure. 2013;22(8):589–600.